	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	4,303	5,166	5,803	5,826	5,749	5,861	7,518	9,111	5,976	6,099	6,130	6,282	6,703	7,235	8,280
Cost of Operating Revenue	2,166	2,531	2,972	3,598	3,027	2,870	3,899	4,648	2,192	2,285	2,303	2,772	2,953	3,135	3,085
Gross Profit	2,138	2,635	2,832	2,228	2,722	2,991	3,619	4,463	3,784	3,813	3,827	3,510	3,750	4,100	5,195
Gross Margin	49.7	51.0	48.8	38.2	47.4	51.0	48.1	49.0	63.3	62.5	62.4	55.9	55.9	56.7	62.7
Total Operating Expenses	3,635	4,362	5,075	5,425	4,748	4,784	6,319	7,718	4,737	4,954	5,306	5,880	6,180	6,428	7,460
Operating Profit	668	804	728	401	1,001	1,077	1,198	1,393	1,239	1,144	824	401	523	807	819
Operating Margin	15.5	15.6	12.5	6.9	17.4	18.4	15.9	15.3	20.7	18.8	13.4	6.4	7.8	11.2	9.9
Financing Income/(Expense) - Net	-258	-368	-463	-348	-401	-345	-267	-197	-166	-240	-189	-161	-223	-203	-212
Profit before Taxes	114	341	207	40	542	738	859	904	1,013	871	630	28	171	981	614
Income Taxes	68	152	70	80	155	163	225	327	407	297	217	93	98	144	217
Profit after Tax	15	153	109	-58	392	576	643	574	898	836	414	-61	77	839	399
PAT Margin	0.3	3.0	1.9	-1.0	6.8	9.8	8.6	6.3	15.0	13.7	6.8	-1.0	1.2	11.6	4.8
EPS - Basic - ex Extraordinary Items	0.91	9.59	6.85	-3.63	25.10	36.93	41.25	36.86	38.05	36.05	26.01	-3.83	4.86	52.98	25.15
EPS - Diluted - ex Extraordinary Items	0.91	9.59	6.85	-3.63	25.08	36.91	41.25	36.86	38.05	36.05	26.01	-3.83	4.85	52.84	25.08
EBIT	668	804	728	401	1,001	1,077	1,198	1,393	1,239	1,144	824	401	523	807	819
EBITDA	889	1,057	1,009	698	1,289	1,365	1,522	1,753	1,670	1,570	1,206	784	905	1,175	1,260
EBITDA Margin	20.7	20.5	17.4	12.0	22.4	23.3	20.3	19.2	28.0	25.7	19.7	12.5	13.5	16.2	15.2

Balance Sheet

Abridged

Understanding Balance Sheet

Jubilant Pharmova Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	R 2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	2,297	2,561	2,928	2,722	2,875	2,948	3,190	4,585	5,038	2,953	3,509	3,762	3,876	3,577	4,109
Long-Term Investments	19	26	34	114	85	103	124	116	77	43	43	33	34	42	91
Property Plant & Equipment - Net	3,116	3,268	3,232	3,195	3,262	3,315	3,493	3,888	4,287	2,575	2,791	3,365	3,687	5,168	6,903
Total Non-Current Assets	5,476	5,810	5,936	5,814	5,949	6,093	6,428	6,884	7,483	5,966	6,482	7,394	7,672	9,179	11,413
Total Assets	7,773	8,371	8,864	8,536	8,824	9,041	9,618	11,469	12,522	8,918	9,991	11,157	11,549	12,756	15,523
Total Current Liabilities	2,213	2,778	3,894	2,105	2,464	1,676	2,005	2,090	2,619	1,049	1,592	1,772	1,889	2,165	2,539
Long Term Debt	2,840	2,469	1,717	3,662	3,013	3,505	3,048	4,243	3,876	2,759	2,676	3,324	3,365	2,389	3,300
Total Non-Current Liabilities	3,234	3,005	2,185	3,939	3,432	3,968	3,578	4,570	4,299	3,128	3,083	3,992	4,238	4,353	5,888
Total Liabilities	5,447	5,783	6,079	6,044	5,896	5,644	5,583	6,659	6,918	4,177	4,674	5,765	6,127	6,518	8,427
Total Shareholders' Equity	2,257	2,476	2,627	2,526	2,966	3,436	4,087	4,809	5,604	4,741	5,319	5,399	5,434	6,255	7,093
Minority Interest	69	112	158	-33	-38	-39	-52	0	-	0	-2	-7	-13	-16	3
Total Equity	2,326	2,588	2,784	2,493	2,928	3,397	4,035	4,809	5,604	4,742	5,316	5,392	5,421	6,239	7,096
Total Liabilities & Equity	7,773	8,371	8,864	8,536	8,824	9,041	9,618	11,469	12,522	8,918	9,991	11,157	11,549	12,756	15,523

Cash Flow

Abridged

Understanding Cash Flow Statement

Jubilant Pharmova Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	651	694	554	358	884	1,006	1,080	1,215	1,422	1,246	885	382	500	763	874
Working Capital - Increase/(Decrease)	-137	-4	-111	96	-133	37	14	-301	-180	250	-178	54	253	112	139
Net CF from Operating Activities	514	690	443	454	751	1,043	1,094	915	1,242	1,496	707	436	753	875	1,013
Capital Expenditures - Net	613	438	284	349	339	462	484	648	568	514	596	796	888	1,111	1,347
Net CF from Investing Activities	-618	-516	-180	-350	-315	-454	-627	-1,021	-352	-743	-384	-554	-634	449	-1,284
Dividends Paid - Cash - Total	37	55	55	54	56	56	56	55	153	1	80	80	80	80	80
Stock - Issuance/(Retirement) - Net	-	-	-	-	20	8	1	266	0	-10	-	-4	-27	-5	-18
Debt - LT & ST - Issuance/(Retirement) - Total	-636	-99	-55	382	-457	-409	-628	662	-573	-1,406	182	162	-82	-1,133	431
Net Cash Flow from Financing Activities	-673	-154	-80	-167	-492	-457	-683	873	-725	-1,417	102	78	-189	-1,217	333
Free Cash Flow to Equity	-735	153	103	487	-45	172	-18	928	102	-424	293	-198	-216	-1,369	97
Free Operating CF net dividend	-137	172	97	26	353	523	549	204	515	967	27	-458	-224	-320	-516
Free Operating CF	-100	227	152	79	409	579	605	259	668	969	107	-378	-144	-241	-436

Business Segment Analysis

FY End:

Mar 25

Jubilant Pharmova Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

CDMO Sterile Injectables (43.2%)₹ 1,397.50 CrCDMO Sterile Injectables (43.2%)₹ 1,397.50 CrRadiopharma (8.6%)₹ 279.40 CrContract research and development services (3.4%)₹ 110.00 CrProprietary Novel Drugs (0.8%)₹ 26.80 CrGenerics (0.4%)₹ 11.90 CrAllergy Immunotherapy (0.4%)₹ 11.60 CrUnallocable (0.1%)₹ 1.90 Cr

Revenue / Sales

Radiopharma (39.8%)₹ 3,388.00 CrCDMO Sterile Injectables (15.0%)₹ 1,271.70 CrCDMO Sterile Injectables (15.0%)₹ 1,271.70 CrContract research and development services (13.5%)₹ 1,151.00 CrAllergy Immunotherapy (8.2%)₹ 701.30 CrGenerics (8.1%)₹ 685.30 CrUnallocated (0.4%)₹ 37.20 Cr

Assets

CDMO Sterile Injectables (25.4%)₹ 4,348.10 CrCDMO Sterile Injectables (25.4%)₹ 4,348.10 CrRadiopharma (16.8%)₹ 2,880.30 CrContract research and development services (10.2%)₹ 1,746.00 CrUnallocable (9.1%)₹ 1,552.00 CrGenerics (6.8%)₹ 1,162.20 CrAllergy Immunotherapy (4.7%)₹ 797.90 CrProprietary Novel Drugs (1.6%)₹ 269.90 Cr

Regional Segment Analysis

FY End:

Mar 25

Jubilant Pharmova Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Americas & Europe (91.1%)₹ 6,593.70 CrRest of the world (5.9%)₹ 428.10 CrIndia (2.9%)₹ 212.70 Cr

Historical Segment Analysis

Track how Jubilant Pharmova Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

CDMO Sterile Injectables	-	-	-	-	-	-	-	-	-	-	86	412	571	1,398
CDMO Sterile Injectables	-	-	-	-	-	-	-	-	-	-	86	412	571	1,398
Radiopharma	-	-	-	-	-	-	-	-	-	-	182	205	200	279
Contract research and development services	-	-	-	-	-	-	-	-	50	99	154	244	151	110
Proprietary Novel Drugs	-	-	-	-	-	-	-	-	9	39	62	34	15	27
Generics	-	-	-	-	-	-	-	-	-	-	144	89	21	12
Allergy Immunotherapy	-	-	-	-	-	-	-	-	-	-	8	25	15	12
Unallocable	-	-	37	69	86	4	1	2	1	0	2	7	7	2
Common	2	1	-	-	-	-	-	-	-	-	-	-	-	-
Performance Chemicals Division	3	0	-	-	-	-	-	-	-	-	-	-	-	-
Pharmaceuticals	280	39	281	229	274	295	326	376	362	441	-	-	-	-
Life Science Ingredients	-	-	149	9	9	77	153	340	197	102	-	-	-	-
Drug Discovery Solutions	-	-	-	-	-	6	13	13	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Jubilant Pharmova Ltd.?

The latest trailing twelve month revenue of Jubilant Pharmova Ltd. is ₹ 8,279.60 Cr, reflecting a 1-year growth of 14.45% and a 3-year CAGR of 9.64%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Jubilant Pharmova Ltd.?

The latest trailing twelve month net profit (PAT) of Jubilant Pharmova Ltd. is ₹ 398.50 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Jubilant Pharmova Ltd.?

The trailing twelve month EBITDA of Jubilant Pharmova Ltd. is approximately ₹ 819.40 Cr (based on an operating margin of 9.90%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Jubilant Pharmova Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Jubilant Pharmova Ltd. is 25.08. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Jubilant Pharmova Ltd.?

The debt-to-equity ratio of Jubilant Pharmova Ltd. stands at 0.51. The interest coverage ratio is 3.87x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Jubilant Pharmova Ltd.?

The estimated book value per share of Jubilant Pharmova Ltd. is 447.79 (derived from a P/B ratio of 2.17 and market price of ₹ 970.75), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Jubilant Pharmova Ltd.?

The trailing twelve month operating cash flow of Jubilant Pharmova Ltd. is ₹ 1,012.90 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Jubilant Pharmova Ltd. report consolidated or standalone financials?

Jubilant Pharmova Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.